医学
中医药
2019年冠状病毒病(COVID-19)
2019-20冠状病毒爆发
大流行
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
传统医学
倍他科诺病毒
梅德林
重症监护医学
替代医学
爆发
冠状病毒感染
预防保健
疾病
病毒学
公共卫生
传染病(医学专业)
政治学
病理
法学
作者
Amin Gasmi,Torsak Tippairote,Pavan Kumar Mujawdiya,Alain Menzel,Roman Lysiuk,Mariia Shanaida,Larysa Lenchyk,Massimiliano Peana,Geir Bjørklund
标识
DOI:10.2174/0929867330666230331084126
摘要
Abstract: The coronavirus disease 2019 (COVID-19) pandemic still has tremendous impacts on the global socio-economy and quality of living. The traditional Chinese Medicines (TCM) approach showed encouraging results during previous outbreaks of Severe Acute Respiratory Syndrome-related Coronavirus (SARS-CoV) and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). With limited treatment availability, TCM herbs and formulations could be useful to reduce COVID-19 symptoms and potential sources for discovering novel therapeutic targets. We reviewed 12 TCM herbs and formulations recommended for COVID-19 management by the National Health Commission and as National Administration of Traditional Chinese Medicine of the People's Republic of China. This article explored the Chinese national authorities' guidelines from 2003 to 2020, the scientific data in public databases for the recommended TCM remedies, and their potential mechanistic actions in COVID-19 management. Several TCM herbs and formulations could potentially benefit COVID-19 management. The recommended TCM oral preparations list includes Huoxiang zhengqi, Jinhua Qinggan, Lianhua Qingwen, and Shufeng jiedu; the recommended injection preparations comprise Xiyanping Xuebijing, Re-Du-Ning, Tanreqing, Xingnaojing, Shenfu, Shengmai, and Shenmai. TCM remedies are viable options for symptom alleviation and management of COVID-19. The current SARS-CoV-2 pandemic presents an opportunity to find novel therapeutic targets from TCM-active ingredients. Despite the recommendations in Chinese National guidelines, these remedies warrant further assessments in well-designed clinical trials to ascertain their efficacy in the treatment of COVID-19.
科研通智能强力驱动
Strongly Powered by AbleSci AI